The next casualty of the overdose crisis could be wildlife conservation

In October 2002, Russian security forces pumped an aerosol into a Moscow theater to subdue Chechen terrorists holding 900 hostages. The chemical cocktail, later identified as containing carfentanil — an opioid 10,000 times more potent than morphine — killed more than 130 hostages. The drug had not been developed for theaters or terrorism, it was developed to anesthetize bears.

That incident set in motion a regulatory logic that continues to reverberate, quietly and lethally, through wildlife medicine 2 decades later. Carfentanil and its common anesthetic counterparts such as etorphine, medetomidine, and xylazine are the pharmacological backbone of modern wildlife immobilization. They are also, increasingly, classified, restricted, or outright banned in the same breath as heroin and fentanyl.

The consequences of that shift are already evident in the field. In his book ‘Exotic Vetting’, wildlife surgeon Romain Pizzi recounts the first giraffe anesthesia death of his 20-year career after etorphine could not be imported into the country where he was working. First synthesized in Edinburgh in the 1960s, etorphine remains one of the very few drugs capable of reliably immobilizing large African megafauna. Two or 3 milliliters can safely anesthetize an adult bull elephant, and for many species there is simply no practical substitute. Yet because it is chemically an opioid, etorphine is increasingly regulated through legal frameworks designed to combat narcotics rather than facilitate wildlife conservation.

Pizzi's account is one among many recurring tragedies of modern wildlife medicine. Across the world, veterinarians working in conservation increasingly contend with delays, shortages, and regulatory barriers surrounding drugs that remain indispensable in the field, leaving conservation interventions subject to the pace of administrative approval in addition to ecological urgency and clinical judgment.

This also happened with xylazine also known as “tranq.” When “tranq” began flooding the illicit supply, individual states scrambled to act, creating a chaotic patchwork of local restrictions. But the real squeeze comes from the federal response. As the DEA moves toward administrative scheduling and Congress advances sweeping federal legislation like the Combating Illicit Xylazine Act, the compliance burden for veterinarians multiplies overnight. Federal Schedule III designation brings strict registration rules, meticulous inventory tracking, ARCOS reporting, and tight transition windows. What is manageable for a large urban clinic with a dedicated administrative team is completely impractical for wildlife veterinarians, whose work is centered on field-based immobilization and translocation programs.

The latest drug to follow that trajectory is medetomidine. In April 2026, the CDC issued a formal health advisory warning about medetomidine (street name “rhino tranq”) appearing in the illicit fentanyl supply across American cities. Medetomidine, an alpha-2 adrenergic agonist developed for veterinary sedation, has now been detected in a 3000% increase in fentanyl samples since 2023.¹ Because its effects are not reversed by naloxone, its emergence presents a new challenge for emergency rooms.²

While the public health concern is legitimate, the regulatory response it will trigger is predictable, and for wildlife medicine, potentially catastrophic. Medetomidine is among the most widely used sedatives in veterinary medicine, relied upon daily in companion animal practice and throughout wildlife conservation, from leopard translocations in India to wolf captures in Scandinavia and field operations across sub-Saharan Africa. When regulators tighten access, as they did with etorphine and ketamine, and slowly follow with xylazine, the wildlife veterinary profession is left without tools or alternatives.

The pattern has been built into the way drug policy is designed. Scheduling frameworks were created for the human pharmaceutical market and calibrated to the risks of addiction, diversion, and overdose in human populations. While veterinary organizations work to preserve access to essential medicines, the regulatory process is largely shaped by the needs of human healthcare and companion animal practice. The logistical realities of wildlife conservation, which include cross-border translocations, field immobilization, remote storage of controlled drugs, and emergency response in free-ranging animals, are rarely considered explicitly when these medicines are evaluated for tighter control. As a result, regulations that are entirely manageable in a hospital or clinic can become significant barriers in conservation settings.

Wildlife veterinarians represent an almost invisible fraction of controlled substance users. They also have almost no specialized professional body with meaningful legislative reach to push back on DEA scheduling decisions. So, when medetomidine goes before a regulatory panel, the voices in the room will be public health officials, law enforcement, and pharmaceutical lobbyists. The wildlife vet working a rhino translocation in Assam or a bear rescue in Laos will not be among them.

What is urgently needed is a tiered regulatory framework that formally distinguishes licensed wildlife veterinary use from illicit diversion, creates expedited international permit pathways for field immobilization drugs modeled on CITES transport provisions, and mandates wildlife veterinary representation in drug scheduling deliberations. The xylazine legislation that the American Veterinary Medical Association negotiated at least attempted to preserve veterinary access while scheduling the drug. It is an imperfect template, but a template, nonetheless.

There is also an opportunity for greater collaboration between wildlife medicine and human healthcare. Atipamezole, the specific reversal agent for medetomidine, is routinely carried by wildlife veterinarians because it provides rapid and reliable reversal of alpha-2 agonist sedation in animals. Although it is not approved for use in humans, its pharmacology and decades of veterinary experience could help inform research into targeted treatments for medetomidine exposure and improve preparedness as drug emergencies become more common. The fact that these conversations remain limited reflects a broader disconnect between human and veterinary medicine, despite growing recognition that many emerging public health challenges increasingly span both fields.

The drugs that move rhinoceroses and sedate wolves were never designed for street corners, yet they are increasingly judged by the harms they cause in one world rather than the lives they save in another. As the boundaries between public health, veterinary medicine, and conservation continue to blur, regulatory systems will have to recognize that these drugs serve fundamentally different purposes in different hands. Until wildlife medicine has a place in those conversations, conservation will continue to inherit policies written for problems it was never meant to solve.

References

1. Medetomidine Surges 3,000% in the US Fentanyl Supply. January 7, 2026. Narcotics. Accessed on July 8, 2026. https://www.narcotics.com/medetomidine-surges-3000-in-the-us-fentanyl-supply/
2. Medetomidine in the U.S. Illegal Fentanyl Supply Increasing Risk for Overdose and Severe Withdrawal Syndrome. April 2, 2026. CDC. Accessed on July 8, 2026. https://www.cdc.gov/han/php/notices/han00527.html